| 1 |
ROS-Targeting Nanozyme Drug Candidate for 2nd Degree Burn Wounds |
| Others-Synth. |
2nd-Degree Burn Wound |
2nd-Degree Burn Wound |
Preclinical |
HTnB Inc. |
RS-2026-25502877 |
|
| 2 |
Clinical Phase 2a Development of BX-001N for the Treatment of Acute Kidney Injury by Inhibiting Ischemia-Reperfusion Injury |
| Others-Synth. |
CSA-AKI |
Reactive Oxygen Species (ROS; H2O2, O2-, •OH, others), Keap1 |
Phase 2 |
Bilix |
RS-2026-25501760 |
|
| 3 |
Nonclinical Development of Enhanced Safety Macrocyclic gadolinium-based contrast agent for hepatobiliary MRI imaging |
| Others-Synth. |
MRI liver imaging |
Gadolinium Based Liver-specific Contrast Agent |
Preclinical |
PharmGen Science, Inc. |
RS-2024-00462636 |
|
| 4 |
A Phase 2b clinical study for iron.based T1.MRI contrast agent: Advancing towards Phase 3 |
| Others-Synth. |
Lymphadenopathy |
Arthrography using magnetic resonance imaging (MRI) for shouler, hip, elbow, knee, wrist, and ankle |
Phase 2 |
Inventera Pharmaceuticals Inc. |
RS-2023-00282888 |
|
| 5 |
Development of a highly stable and safe macrocyclic gadolinium-based contrast agent for hepatobiliary MRI imaging |
| Others-Synth. |
MRI contrast agent |
Gd-ligand |
Candidate |
PharmGen Science, Inc. |
HN22C0196 |
|
| 6 |
Development of a HNP-2006 contrast agent with improved safety |
| Others-Synth. |
MRI contrast agent |
Gd-ligand |
Phase 2 |
Hana Pharm Co., Ltd. |
HN21C1298 |
|